Announcement on Change of Sponsor Representative
Filed with SSE · · 3 pages · Chinese
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Announcement on Expected Increase in Performance for 2025
- Announcement on Obtaining the Ethiopian Drug Registration Approval for Insulin Glargine Injection and Its Pre-filled Injection Pen
- Announcement on Obtaining of European Commission Marketing Authorization for Insulin Glargine Injection
- Announcement on Progress in Redemption of Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
- Announcement on the Dismissal of Senior Management Member and Designation of Designated Personnel to Assume the Duties of the Financial Director
Later from Gan & Lee Pharmaceuticals
- Announcement on Positive Opinion from the European Medicines Agency's CHMP on the Marketing Authorization Application for Insulin Lispro Injection (Bysumlog®) and Insulin Aspart Injection (Dazparda®)
- Announcement on Appointment of Senior Management Members
- Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
- Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
- Announcement on the Company Passing ANVISA GMP Certification
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals